Literature DB >> 9713947

Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan.

D B Lin1, H M Wang, Y L Lee, U P Ling, S P Changlai, C J Chen.   

Abstract

A mass hepatitis B vaccination program began in Taiwan in 1984. In order to determine the immune status of hepatitis B virus (HBV) infection among preschool children, a total of 25 kindergartens in 20 townships and metropolitan precincts in central Taiwan were randomly selected through stratified sampling. Serum specimens of 2130 healthy preschool children aged 2-6 years old were screened for the HBV markers and liver function in 1996. HBV surface antigen (HBsAg), antibody against HBsAg (anti-HBs) and antibody against HBV core antigen (anti-HBc) were tested by reverse passive hemagglutination (RPHA), enzyme immunoassay (EIA) and radioimmunoassay (RIA) using commercial kits. HBV vaccination rate of the preschool children was 98%, and complete vaccination rate (three or four doses of HBV vaccine) was 94%. The HBsAg seropositive rate was 4.5% among incomplete vaccinees and 1.3% among complete vaccinees. The anti-HBs was detectable in 1637 of 2000 complete vaccinees (81.9%) and in 53 of 88 incomplete vaccinees (60.2%). The overall prevalence rate of anti-HBc was 2.4% (52 of 2130). The older the age, the lower the anti-HBs seropositive rate. The anti-HBs seropositive rats for complete vaccinees were 100% at 2 years old and 75% at 6 years old. There were no significant differences in HBsAg-seropositive rates and anti-HBs-seropositive rates among different residential areas or ethnic groups. There were three children who were seropositive on HBsAg, anti-HBs and anti-HBc, whether they were infected by the vaccine-induced escape mutant of HBV deserves scrutiny.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713947     DOI: 10.1016/s0264-410x(98)00050-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  Long-term persistence of immunity after hepatitis B vaccination: Is this substantiated by the literature?

Authors:  Terence T Lao
Journal:  Hum Vaccin Immunother       Date:  2017-03-01       Impact factor: 3.452

3.  Immune persistence after hepatitis B vaccination in infancy - Fact or fancy?

Authors:  Terence T Lao
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

4.  Seroepidemiology of HBV infection in South Korea, 1995 through 1999.

Authors:  M K Jang; J Y Lee; J H Lee; Y B Kim; H Y Kim; M S Lee; C K Park; J Y Yoo
Journal:  Korean J Intern Med       Date:  2001-09       Impact factor: 2.884

5.  Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China.

Authors:  Terence T Lao; Daljit S Sahota; Lai-Wa Law; Yvonne K Y Cheng; Tak-Yeung Leung
Journal:  Bull World Health Organ       Date:  2014-09-03       Impact factor: 9.408

6.  The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study.

Authors:  Wen-Kuan Huang; Hung-Chih Hsu; Jia-Rou Liu; Tsai-Sheng Yang; Jen-Shi Chen; John Wen-Cheng Chang; Yung-Chang Lin; Kuang-Hui Yu; Chang-Fu Kuo; Lai-Chu See
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Impact of neonatal hepatitis B vaccination programme on age-specific prevalence of hepatitis B infection in teenage mothers in Hong Kong.

Authors:  T T Lao; D S Sahota; S S H Suen; P K S Chan; T Y Leung
Journal:  Epidemiol Infect       Date:  2012-12-05       Impact factor: 4.434

8.  Hepatitis B virus vaccination booster does not provide additional protection in adolescents: a cross-sectional school-based study.

Authors:  Yung-Chieh Chang; Jen-Hung Wang; Yu-Sheng Chen; Jun-Song Lin; Ching-Feng Cheng; Chia-Hsiang Chu
Journal:  BMC Public Health       Date:  2014-09-23       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.